NeurologyLive® Friday 5 — August 16, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Virtual Reality is a Game-Changer During Blood Draws for Pediatric Patients With Spinal Muscular Atrophy

In honor of Spinal Muscular Atrophy (SMA) Awareness Month, Abraham Homer, the gaming technology supervisor and creative technologist at Children's Hospital Colorado, shared how virtual reality transformed care for patients with SMA.

2: Challenges in Early Diagnosis of Frontotemporal Dementia in Clinical Settings: Chris Berka

The CEO and cofounder at Advanced Brain Monitoring talked about how the early diagnosis of frontotemporal dementia is often mistaken for Alzheimer disease, but advancements in neuropsychological assessments and biomarker identification may improve accuracy. [WATCH TIME: 4 minutes]

3: Continued Evolution of Deep Brain Stimulation in Neurology: Jonathan Jagid, MD; Brian Noga, PhD

A pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]

4: NeuroVoices: Chris Berka on Advancing Early Detection of Neurodegenerative Diseases with EEG Biomarkers

The CEO and cofounder at Advanced Brain Monitoring talked about a study presented at AAIC 2024 that explored the use of EEG biomarkers to differentiate between Alzheimer disease and frontotemporal dementia.

5: Significance of Newly Approved IPX203 for Parkinson Disease

In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.